



Standard Operating Procedure: SAE reporting SOP

Purpose

The purpose of this SOP is to guide reporting of serious adverse events (SAEs) and grade 4 toxicity events in the study.

Intended Users

Clinicians, nursing staff

Responsibility

- This SSP applies to all clinicians and nursing staff, involved in the clinical management of study participants.
- SAE and toxicity forms will be completed by clinicians at site as close to the occurrence as possible.
- A summary report of all SAEs and suspected toxicity events will be reported every 3 months to the LSM, the national ethics and regulatory committees and sponsor.
- The Principal Investigator through the lead clinician retains the overall responsibility on implementation of this SOP.

Definitions

- **AEs** Adverse Events
- **LSM** Local Safety Monitor
- **DSMB** Data & Safety Monitoring Board
- **PI** Principal Investigator
- **SAEs** Serious Adverse Events
- **SOP** Study Operating Procedure
- **SUSAR** Suspected and Unexpected Serious Adverse Reaction
- **Serious Adverse Event (SAE):** Any untoward medical occurrence or effect that is:
 - i. Death (from any cause at any time)
 - ii. Life-threatening event (i.e., the subject was, in the view of the investigator, at immediate risk of death from the event that occurred).



CHAIN PB-SAM

Standard Operating Procedure: SAE reporting SOP

- iii. Persistent or significant disability or incapacity (i.e., substantial disruption of ability to carry out normal life functions).
- iv. Hospitalization or an important medical event requiring medical or surgical intervention to prevent one of the outcomes listed above. Examples include severe adverse drug reactions such as severe allergic reaction or blood dyscrasias requiring intensive treatment.

Required Materials

Serious Adverse Events Form

- Toxicity form
- Pens

Procedure

- Children admitted to hospital with complicated SAM are highly likely to experience many clinical events and deteriorations including mortality, often related to their background clinical condition. The PB-SAM study will use marketed products that are routinely used for the treatment of other ailments. The products has excellent safety profile. However, there are rare reported toxic events that could result from the trial drugs.
- Serious Adverse Events and grade 4 toxic events will be documented.
- **SAE/Toxicity/SUSAR reporting**
 1. If an adverse event occurs in a participant and meets the criteria for SAE (see definition above) or grade 4 toxic event (see appendix 1 below) the clinician should consider this as an SAE/toxic event requiring reporting. Some toxic events may require reporting in addition as an SAE where they meet the criteria for an SAE.
 2. Should there be an emergency or serious safety concern the clinical lead/ chief investigator /LSM should be informed immediately when the event is identified.
 3. The site clinician will document the event in the patient's ward file / clinical notes, the investigations done and the management of the SAE. This should continue throughout the progress of the event until an outcome is arrived. Recording will also begin the SAE CRF/toxicity form CRF whichever applicable.
 4. At resolution of the event, the clinician will summarize the entire SAE/grade 4 toxic

CHAIN PB-SAM
Standard Operating Procedure: SAE reporting SOP



- event in the SAE form/toxicity form of the CRF or both where applicable.
5. Data entry will be done in the eCRF/ database once entry in SAE/toxicity form has been completed. The P.I or designee will compile a summary of all SAEs and suspected grade 4 toxic events which will be reported every 3 months. The report will include the site; study number; date of event; subject details (initials, sex and age); nature of event; relevant history; outcome and a judgement of causality. This report will be sent to the LSM, DSMC, the ethical research committees and regulatory committees. If the PI/designee requires further details, clinical notes or their scan shall be provided to contribute to report writing.
 6. SAEs that are deemed causally related to the study drug and SUSARs will be initially reported to the sponsor, DSMC and regulatory bodies within 7 days of the investigators becoming aware of the event with a follow up report being provided within a further 8 calendar days.

Appendices

Appendix 1: Pre-defined Grade 4 suspected toxicity events

New episodes of:

Allergic and Cutaneous reactions one or more of:	<ul style="list-style-type: none"> • Anaphylaxis • Bronchospasm requiring treatment • Exfoliative dermatitis 		
Severe anaemia	<ul style="list-style-type: none"> • Severe anaemia 	Hb	<4g/dl
Neutropenia	<ul style="list-style-type: none"> • Neutrophil count 		<0.4 x 10 ⁹ /L
Thrombocytopenia	<ul style="list-style-type: none"> • Platelets 		<25 x 10 ⁹ /L
Encephalopathy & Neurological one or more of:	<ul style="list-style-type: none"> • Impaired consciousness: • Convulsions • New focal neurological signs 	AVPU	P or U
	<ul style="list-style-type: none"> • >3.5 x upper limit of normal: 	Creatinine	>138 µmol/L
Abnormal liver function one or more of:	<ul style="list-style-type: none"> • >10 x upper limit of normal: 	ALT	>450 IU/L
		AST	>620 IU/L
		ALP	>4,060 IU/L
	<ul style="list-style-type: none"> • >5 x upper limit of normal: 	Bilirubin	>63 µmol/L

CHAIN PB-SAM
Standard Operating Procedure: SAE reporting SOP



SOP AWARENESS LOG

I, the undersigned below, hereby confirm that I am aware that the accompanying SOP is in existence from the date stated herein and that I shall keep abreast with the current and subsequent SOP versions in fulfilment of Good Clinical Practice (GCP).

Number	Name	Signature	Date (dd/mmm/yyyy)
1.			
2.			
3.			
4.			
5.			
6.			
7.			
8.			
9.			
10.			
11.			
12.			
13.			
14.			